Cerus (CERS) Reaches $5.66 After 7.00% Up Move; Last Week Celyad SA (CYAD) Coverage

March 23, 2018 - By olga

The stock of Cerus Corporation (NASDAQ:CERS) is a huge mover today! The stock increased 2.35% or $0.13 during the last trading session, reaching $5.66. About 431,475 shares traded. Cerus Corporation (NASDAQ:CERS) has declined 40.83% since March 23, 2017 and is downtrending. It has underperformed by 57.53% the S&P500.The move comes after 7 months positive chart setup for the $733.52M company. It was reported on Mar, 23 by Barchart.com. We have $6.06 PT which if reached, will make NASDAQ:CERS worth $51.35 million more.

Among 2 analysts covering Celyad SA (NASDAQ:CYAD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celyad SA had 2 analyst reports since August 27, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 31 by Piper Jaffray. See Celyad SA (NASDAQ:CYAD) latest ratings:

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on May, 2. They expect $-0.12 EPS, up 33.33% or $0.06 from last year’s $-0.18 per share. After $-0.10 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Among 5 analysts covering Cerus (NASDAQ:CERS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cerus has $8 highest and $4.0 lowest target. $5.75’s average target is 1.59% above currents $5.66 stock price. Cerus had 11 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Buy” on Monday, October 30. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Wednesday, January 24 by Robert W. Baird. Zacks downgraded the stock to “Buy” rating in Tuesday, August 11 report. The stock of Cerus Corporation (NASDAQ:CERS) earned “Buy” rating by Cantor Fitzgerald on Monday, January 8. Cowen & Co maintained it with “Buy” rating and $6.0 target in Thursday, October 5 report. The stock of Cerus Corporation (NASDAQ:CERS) earned “Buy” rating by Cantor Fitzgerald on Wednesday, June 7. The company was downgraded on Thursday, December 17 by Wedbush. The stock has “Buy” rating by BTIG Research on Friday, May 26. Robert W. Baird maintained Cerus Corporation (NASDAQ:CERS) on Thursday, November 30 with “Buy” rating. The firm has “Buy” rating by BTIG Research given on Wednesday, August 19.

Investors sentiment increased to 1.45 in 2017 Q3. Its up 0.13, from 1.32 in 2017Q2. It improved, as 9 investors sold Cerus Corporation shares while 22 reduced holdings. 11 funds opened positions while 30 raised stakes. 57.26 million shares or 0.28% less from 57.42 million shares in 2017Q2 were reported. Nationwide Fund holds 58,916 shares or 0% of its portfolio. Ubs Asset Mgmt Americas has invested 0% in Cerus Corporation (NASDAQ:CERS). Proshare Advisors Ltd owns 68,562 shares. Tiaa Cref Inv Mngmt Ltd Llc stated it has 356,854 shares or 0% of all its holdings. Envestnet Asset Inc has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Dekabank Deutsche Girozentrale accumulated 48,000 shares. Lakeview Ptnrs Lc holds 26,051 shares or 0.06% of its portfolio. Moreover, Raymond James has 0% invested in Cerus Corporation (NASDAQ:CERS). The Illinois-based Citadel Lc has invested 0% in Cerus Corporation (NASDAQ:CERS). Great West Life Assurance Com Can owns 8,200 shares for 0% of their portfolio. Cannell Peter B & holds 0.01% or 105,000 shares. Vanguard Group Inc Incorporated invested in 4.94 million shares or 0% of the stock. Parametric Portfolio Associates Lc owns 67,756 shares or 0% of their US portfolio. Swiss Bancshares owns 158,900 shares. Raub Brock Capital Mgmt L P has 29,399 shares for 0.02% of their portfolio.

Since March 10, 2018, it had 1 buying transaction, and 5 selling transactions for $597,723 activity. 17,766 shares were sold by Greenman William Mariner, worth $87,795. Green Kevin Dennis sold $23,409 worth of stock or 4,737 shares. The insider Moore Carol sold $23,151. 150,011 shares were bought by CORASH LAURENCE M, worth $773,199 on Monday, March 12. Menard Chrystal sold $22,793 worth of Cerus Corporation (NASDAQ:CERS) on Saturday, March 10. $18,328 worth of Cerus Corporation (NASDAQ:CERS) was sold by Benjamin Richard J.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $733.52 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News